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Abstract
Background/Aims: There is growing interest in the use of adaptive designs to improve the efficiency of clinical trials.
We apply a Bayesian decision-theoretic model of a sequential experiment using cost and outcome data from the
ProFHER pragmatic trial. We assess the model’s potential for delivering value-based research.
Methods: Using parameter values estimated from the ProFHER pragmatic trial, including the costs of carrying out the
trial, we establish when the trial could have stopped, had the model’s value-based stopping rule been used. We use a
bootstrap analysis and simulation study to assess a range of operating characteristics, which we compare with a fixed
sample size design which does not allow for early stopping.
Results: We estimate that application of the model could have stopped the ProFHER trial early, reducing the sample
size by about 14%, saving about 5% of the research budget and resulting in a technology recommendation which was the
same as that of the trial. The bootstrap analysis suggests that the expected sample size would have been 38% lower, sav-
ing around 13% of the research budget, with a probability of 0.92 of making the same technology recommendation deci-
sion. It also shows a large degree of variability in the trial’s sample size.
Conclusions: Benefits to trial cost stewardship may be achieved by monitoring trial data as they accumulate and using a
stopping rule which balances the benefit of obtaining more information through continued recruitment with the cost of
obtaining that information. We present recommendations for further research investigating the application of value-
based sequential designs.
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Introduction and background
There is growing interest in the use of adaptive designs
to improve the efficiency of clinical trials. Adaptive
designs involve monitoring outcome data as they accu-
mulate, permitting changes to be made to the trial –
such as varying the allocation ratio, or stopping early –
in response to the evolving evidence. A large literature
surveys their development and application and the
potential they offer for improving efficiency.1–8
Despite this interest, little attention has been paid to
how statistical decision rules in an adaptive clinical trial
might formally account for the costs and benefits of the
trial itself. This hampers assessment of the value that
such designs might create for health care systems. A
growing number of theoretical papers, some with illus-
trative applications, have proposed the use of value-
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based criteria for fixed sample size designs,9–11 as well
as adaptive ones.12,13 However, lack of guidance on
how research costs should be measured and how accu-
mulating evidence about treatment costs and health
outcomes may inform decision rules as a trial pro-
gresses, means that incorporation of costs and benefits
in adaptive clinical trials remains an under-researched
area. The United Kingdom’s National Institute for
Health Research has recognised this and has recently
provided ‘Annual Efficient Studies’ funding to clinical
trials units to investigate further. The ‘Costing
Adaptive Trials’ (CAT) project14 will provide costing
guidance; the ‘EcoNomics of Adaptive Clinical Trials’
(ENACT) project15 will assess how cost-benefit criteria
may be incorporated.
In this article, we apply a recent contribution proposing
a Bayesian decision-theoretic model of a sequential clinical
trial13,16 – (a sequential trial is a special kind of adaptive
trial in which data are monitored as they accumulate over
a sequence of interim analyses – using retrospective data
from the) PROximal Fracture of the Humerus: Evaluation
by Randomisation (ProFHER) pragmatic trial. The
ProFHER trial was a multicentre randomised clinical trial
conducted in the United Kingdom National Health
Service which compared surgery with sling immobilisation
for the treatment of displaced proximal humeral frac-
ture.17–19 We believe that the application is the first of its
kind to use research cost data to inform this model. It is
presented as a ‘proof of concept’ study which contributes
to the gap in the literature discussed above.
The ProFHER trial was designed according to stan-
dard criteria for a fixed sample size clinical trial.
However, by considering how the effectiveness and
research cost data accumulated over the course of the
trial, we can estimate when the trial could have stopped,
had a decision rule based on evaluating the cost-
effectiveness of the research process been used. Our
interest is not in whether such a rule could replace a
fixed sample size, or group sequential, clinical trial
designed according to traditional criteria. Rather, we
are interested in whether such a rule could complement
such designs, by providing additional information to
trials teams about whether interim evidence suggests
that the benefit of randomising further patients into the
trial is worth the cost. This matter is of particular inter-
est for trials such as the ProFHER trial, where the extra
costs associated with surgery and subsequent revision
and secondary surgery, compared with the cheaper
alternative of sling immobilisation, meant that while
accumulating clinical evidence may not have suggested
that one treatment was superior to the other, accumu-
lating cost-effectiveness evidence might have done.
Further, patient and surgeon preferences for the two
sharply contrasting treatment options were expected to
be a major threat to completing successfully recruit-
ment into the trial. Hence a value-based stopping rule
might have been useful.
Methods
The Bayesian model
Chick et al.13 model a two-armed sequential clinical
trial in which patients are randomised, in a pairwise
and sequential manner, to a new health technology, N,
and a control (or standard) health technology, S.
Follow-up of health outcomes and treatment costs for
each patient occurs after D ø 0 units of time. To reflect
beliefs concerning the cost-effectiveness of the technolo-
gies before starting the trial, the model places a prior
distribution on the expected value of the net monetary
benefit of N minus that of S, where net monetary bene-
fit for technology i 2 fN, Sg is defined as lEi  Ci,
where E is a random variable denoting effectiveness, C
is a random variable denoting treatment cost and l is
the willingness to pay for an additional unit of effective-
ness in the jurisdiction of interest (e.g. following advice
for the United Kingdom National Health Service,20 the
ProFHER trial set l equal to £20,000 per Quality
Adjusted Life Year (QALY)).
The objective of the model is to obtain a rule to halt
recruitment to the trial. This rule maximises the
expected net benefit of carrying out the trial and then
recommending one of the two technologies on cost-
effectiveness grounds for the treatment of P patients
who are expected to benefit from the adoption decision.
The costs of carrying out the trial and the costs incurred
in switching technologies are included in the measure of
expected net benefit. The Supplemental Material dis-
cusses the model’s objective function in more detail.
The trial can make a maximum number of Qmax
pairwise allocations. The outcome of interest is incre-
mental net monetary benefit, X, the difference between
the net monetary benefit of N and S. For pairwise allo-
cation j, j= 1 , 2 , . . . ,Qmax , this is
Xj = l EN, j  ES, j
 
 CN, j  CS, j
 
ð1Þ
We assume that X has a normal distribution and
that its expected value, W, is unknown and its variance,
s2X , is known. Before starting the trial, beliefs about W
are modelled using a normal prior distribution with an







the ‘effective sample size’, measured in pairwise alloca-
tions, of the prior distribution.
Assuming a fixed rate of recruitment to the trial, we
may express the delay in terms of time, D, or pairwise
allocations, tø0 . The trial comprises three distinct
stages:
1. Stage I: patients are recruited and randomised, but
no patient-level health outcome or treatment cost
data are observed owing to the delay in following
up;
2. Stage II: patient-level health outcome and treat-
ment cost data are observed and are used to update
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the prior distribution using Bayes’ rule. There is
the option to randomise another pair of patients,
or to stop recruitment to the trial. Define x as an
observation of incremental net monetary benefit.
Then the posterior mean for expected incremental







If, during Stage II, the expected benefit of randomis-
ing a further pair of patients is less than the cost, Stage
II finishes, having made T pairwise allocations, and the
trial moves to Stage III.
1. Stage III: health outcome and treatment cost data
for patients in the ‘pipeline’ – those who have been
treated but whose outcomes are yet to be observed
– are observed and Bayesian updating continues.
T is chosen so that the overall expected value of the
trial – the total incremental expected benefit which
accrues to the P patients, minus the fixed (cfixed) and
variable (c) research costs, together with any costs I
incurred in adopting one of the two technologies – is
maximised. The decision rule fully accounts for the
uncertainty in the data generating process and the prior
distribution for expected incremental net monetary
benefit. We call a rule which meets this objective an
‘Optimal Bayes Sequential policy’ and obtain such a
policy using dynamic programming methods.13
There are two scenarios in which it is not optimal to
enter Stage II: (1) the expected benefit from entering
Stage II is less than that of running a trial with a fixed
number of pairwise allocations in the range (0, t). In
this scenario, the Optimal Bayes Sequential policy
selects the same sample size as a trial designed to maxi-
mise the difference between the expected value of sam-
ple information and the cost of sampling.9–11 We call
this an ‘Optimal Bayes One Stage’ design; (2) the value
of the prior mean favours one of the two technologies
so strongly that the expected cost of conducting any
trial outweighs the expected benefit. In this scenario,
the Optimal Bayes Sequential policy is to run no trial
and base the adoption decision on the sign of the prior
mean alone.
Figure 1 presents a representation of the stopping
policy for the problem in (pairwise allocations 3
prior/posterior mean) space. If it is optimal to run a
sequential trial, recruitment of patients takes place dur-
ing Stage I but no outcomes are observed. At the start
of Stage II, health outcomes and treatment costs for
the first pairwise allocation are observed and used to
update the prior mean. Outcomes then arrive sequen-
tially, the posterior mean is updated sequentially and
interim analyses of the data are permitted. As long as
the posterior mean lies within the area defined by the
stopping boundary (we refer to this as the ‘continuation
region’), it is optimal to continue recruitment. Once the
posterior mean crosses the boundary, it is optimal to
halt recruitment and move to Stage III. There is no lon-
ger a continuation region in Stage III because recruit-
ment is no longer taking place. In the analysis that
follows, for consistency with the ProFHER application,
we assume that the cost of switching technologies, I, is
equal to zero. This means that, once outcomes for all
patients in the trial have been observed, the cost-
effectiveness of the new technology is judged according
to whether or not the posterior mean is greater than
zero. If it is greater than zero, the new technology is
deemed to be cost-effective; if not, the standard tech-
nology is deemed to be cost-effective.
The letters ‘A’ to ‘D’ in Figure 1 denote ranges for
the prior mean m0 which define the optimal choice of
trial design. If m0 lies between points ‘C’ and ‘D’, it is
optimal to run the sequential trial, with the starting
point for the path of the posterior mean in Stage II
being determined by the value of m0. If m0 lies between
‘A’ and ‘C’ or ‘D’ and ‘B’, it is optimal to run the
Optimal Bayes One Stage design. If m0 lies above A or
below B, no trial should be run and the adoption deci-
sion should be based on the value of the prior mean
alone: above A, prior information is strong enough to
Figure 1. Stopping boundary for the Optimal Bayes Sequential
model, showing the three stages of the trial (marked ‘I’, ‘II’ and
‘III’) and the continuation region. Stages II and III are shown
assuming that the sequential trial stops at the maximum sample
size of Qmax pairwise allocations. t is the delay, measured in
terms of the number of pairwise allocations, in observing the
health outcome and treatment cost for each pairwise allocation.
Interim analyses to inform early stopping are permitted during
Stage II as outcomes are observed.
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favour immediate adoption of N; below B, it is strong
enough to favour immediate adoption of S.
The shape of the stopping boundary and the ranges
for m0 over which each of the three trial designs is opti-
mal are a function of the model’s parameter values and
so will vary across applications. Where there exists a
large degree of uncertainty over the values of a particu-
lar parameter, sensitivity analysis may be carried out.13
The application
The ProFHER trial. Between September 2008 and April
2011, 250 patients aged 16 years and older who pre-
sented to orthopaedic departments in United Kingdom
National Health Service hospitals with a displaced
proximal humeral fracture were randomised to either
(1) surgical treatment, which consisted of fracture fixa-
tion with plate and screws to preserve the humeral
head, or humeral head replacement, followed by active
rehabilitation, or (2) non-surgical treatment, which con-
sisted of sling immobilisation for the injured arm for as
long as was thought necessary, followed by active reha-
bilitation. Following discussions with the funder, it was
agreed that a single follow-up time point would not be
specified for the primary health outcome measure, the
Oxford Shoulder Score. Rather, follow-up points were
fixed at 6, 12 and 24 months. Analysis of clinical and
cost-effectiveness used the intention to treat principle
(during the trial, 16 patients randomised to surgery
switched to sling and 2 randomised to sling switched to
surgery).17–19 The economic evaluation consisted of a
cost-utility analysis which took the National Health
Service perspective. The European Quality of Life-5
Dimensions-3L instrument was used to obtain the
QALYs at 3, 6, 12 and 24 months using the area under
the curve method.
The trial’s results suggested that there was no differ-
ence between surgical intervention and sling, as mea-
sured by the average value of the Oxford Shoulder
Score at the three follow-up points. Surgical interven-
tion for one patient cost an estimated £1758 more than
sling (95% confidence interval = (£1126, £2389)) and
yielded an estimated 0.0101 fewer QALYs (95% confi-
dence interval = (20.13, 0.11)). A 5-year follow-up
found the main results unchanged.22
The ProFHER trial was funded by the National
Institute for Health Research, with a total budget of
£1,485,585. Figure 2 shows how the research budget
spend accumulated over the lifetime of the project (left
axis, continuous black line), together with the path for
the cumulative estimate of incremental net monetary
benefit at 1 year (right axis, dashed blue line), measured
in blocks of 10 patient pairs at a time.* Positive values
suggest that surgery is cost-effective. Key milestones in
the project are denoted by the letters ‘A’ to ‘E’. The
research costs plotted in Figure 2 are those relating to
the research budget itself. Treatment costs were not
charged to this budget, rather they were funded as part
of normal commissioning arrangements within the
National Health Service. For the purposes of this work,
we assume that treatment costs would have been the
same with or without the trial, on average, across the
hospitals participating in the trial.
The path of the cumulative estimate of expected
incremental net monetary benefit shown in Figure 2
was not available to the investigators as the trial pro-
gressed. The path shows that, although surgery
appeared cost-effective initially, the estimate favoured
sling by late 2010 and remained that way for the rest of
the follow-up. Viewed in terms of incremental effective-
ness versus incremental cost at 1 year, the overall story
of the trial is that there was no evidence that surgery
was more effective than sling (using both the primary
health outcome measure and QALYs), but there was
strong evidence that surgery was more costly than
sling. The Supplemental Material provides further
details about how the differences between the estimates
of incremental QALYs, Oxford Shoulder Score and
treatment costs evolved.
Estimation of parameter values. Using the research cost
data from the trial, we estimated that costs of approxi-
mately £161,000 were incurred prior to the recruitment
of the first patients in September 2008 (labelled as ‘A’
in Figure 2). During the recruitment phase (which fin-
ished in April 2011, labelled ‘B’) and the 2-year follow-
Figure 2. Cumulative budget spend for the ProFHER trial (left
axis, continuous line) and average of incremental net monetary
benefit at 1 year (right axis, dashed blue line, plotted in blocks
of 10 patient pairs, 10 receiving surgery and 10 receiving sling).
Key milestones: ‘A’ – recruitment starts; ‘B’ – recruitment
finishes; ‘C’ – 1 year follow-up finishes; ‘D’ – 2 year follow-up
finishes; ‘E’ – publication of principal articles.17,18
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up phase (which finished in April 2013, labelled ‘D’),
further costs of approximately £1,020,000 were
incurred. The main results17,18 were reported 2 years
later (‘E’), and the project concluded at the end of
December 2016. Approximately £289,000 of costs were
incurred post follow-up. These covered the tasks of
data preparation, cleaning, analysis and report writing.
The total spend was approximately £1,470,000. We
assume that the costs incurred during the recruitment
and follow-up phases were split 50:50 between fixed
and variable costs, which implies an estimate of an
average cost per pairwise allocation of c= £4, 080 .
For the purposes of exposition, we assume that the
delay D is equal to 1 year. We estimate that the rate of
recruitment is approximately 47 pairwise allocations
per year, so that t = 47 pairwise allocations. We
assume a near non-informative prior, setting m0 = 0
and n0 equal to two pairwise allocations, representing
the lack of evidence for cost-effectiveness at the start of
the trial. The other parameter values used for the appli-
cation, together with their sources and the assumptions
used to obtain them, are reported in Supplemental
Table 2 of the Supplemental Material and accompany-
ing discussion.
Implementation of the model. We take the perspective of
the ProFHER researchers prior to commencing the
trial, but post trial commissioning. That is, we assume
that a decision to commission the research and commit
fixed costs cfixed has already been taken. The solution
to the model permits interim analyses to be made at
any point during Stage II, including one pairwise allo-
cation at a time. For the purposes of illustration, we
assume that interim analyses take place once every 10
pairwise allocations.
We run two versions of the model. The first assumes
that the maximum number of pairwise allocations that
can be made, Qmax , is equal to 125, that is, the sample
size of the ProFHER trial itself. The second assumes
that Qmax is equal to 250, that is, double this maxi-
mum sample size. We ran the latter version of the
model to test the sensitivity of results to a design which
permits the stopping time to exceed that of the
ProFHER trial. Matlab code which implements the
computations is provided at https://github.com/
sechick/htadelay.
Results
When would the Bayesian sequential version of the
ProFHER trial have stopped?
Figure 3 plots the Stage II stopping boundaries for the
two versions of the model. Also drawn is the path of
the posterior mean for expected incremental net mone-
tary benefit, derived using the data as it accumulated in
the ProFHER trial (continuous black line, markers:
‘8’). This is drawn using the summary data for effective-
ness and treatment costs from the trial, arranged in
blocks of 10 pairwise allocations, and reported in
Supplemental Table 1 of the Supplemental Material.
The other paths in Figure 3 are described in the next
section. Figure 3 shows that doubling the maximum
sample size from 125 to 250 pairwise allocations has lit-
tle impact on the shape and location of the stopping
boundary between the start of Stage II and
Qmax = 125.
The first point on the path for the posterior mean,
at the start of Stage II and at an effective sample size of
49 pairwise allocations (equal to n0 = 2 plus the delay
of 47 pairwise allocations), is equal to the prior mean
(m0 = 0 ). Figure 3 shows that, independently of
whether Qmax = 125 or 250, Stage II would have con-
cluded after 107 patient pairs had been recruited, with
a posterior mean equal to 2£1110. This is shown by
the interim analysis marked ‘X’ in Figure 3 and corre-
sponds to the first point at which the posterior mean
lies outside the stopping boundary. Follow-up of the 47
patient pairs in the pipeline is shown by the remaining
circles on the path and would have led to a posterior
mean for expected incremental net monetary benefit
equal to approximately 2£1810, suggesting that sur-
gery is not cost-effective. Hence, irrespective of whether
Qmax is set to be 125 or 250 pairwise allocations, the
sequential trial would have stopped early, with no
change in the technology recommendation and little
change in the estimate of cost-effectiveness, saving 18
patient pairs (14% of the trial’s actual sample size) and
approximately 18 3 £ 4, 080 = £ 73, 000 (5% of the
total cost of the trial).
Bootstrap analysis
To investigate the degree of variability in the sample
size and other operating characteristics, we used a non-
parametric bootstrap analysis. We sampled at random,
and with replacement, from the data in Supplemental
Table 1 of the Supplemental Material and obtained
5000 bootstrapped paths for the posterior mean. For
each path, we compared the posterior mean with the
stopping boundary, assuming it would be practical to
run interim analyses in blocks of 10 pairwise alloca-
tions. For each interim analysis, we established when
Stage II would have stopped, as well as the adoption
decision, cost of the trial and the posterior mean for
expected incremental net monetary benefit at the end
of Stage III. Three bootstrapped paths are shown in
Figure 3 for a trial with Qmax = 125, with interim and
follow-up analyses marked. Resampled Path 3 (cyan
and marked ‘8’) stops the trial at the third interim anal-
ysis, having crossed the upper part of the boundary;
resampled Path 1 (magenta and marked ‘+ ’) stops at
the second interim analysis, having crossed the lower
part of the boundary; and resampled Path 2 (green and
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marked ‘’) runs to the maximum sample size. Paths 1
and 3 suggest that sling is cost-effective at the end of
follow-up (the posterior mean is negative); Path 2 sug-
gests that surgery is cost-effective (the posterior mean
is positive).
Some operating characteristics are summarised in
Table 1, labelled ‘bootstrap’. They show that, when
Qmax = 250 , the average sample size of the Optimal
Bayes Sequential design is 77 pairwise allocations (min-
imum 57; maximum 250), 38% lower than the trial’s
actual sample size. The expected saving in the trial’s
budget resulting from the reduced sample size is esti-
mated to be £196,000 (13% of the research budget).
The posterior mean for expected incremental net mone-
tary benefit at the end of Stage III is estimated to be
2£1853. This design recommended sling for 92% of
the bootstrapped paths, with 82% of the paths
stopping having first crossed the lower part of the stop-
ping boundary. Also shown in Table 1 are the operat-
ing characteristics for a fixed sample size trial in which
each resampled path in the bootstrap analysis runs to
Qmax = 250 pairwise allocations: 99.3% of paths con-
clude with a recommendation of sling, but this improve-
ment is achieved at a cost of approximately £706,000
((250 2 77) 3 £4080) when compared with the
Optimal Bayes Sequential design.
Figure 3 showed that there is very little difference
between the stopping boundary when the maximum
sample size is reduced to that used in the ProFHER
trial itself (Qmax = 125 pairwise allocations). Table 1
shows that, when Qmax = 125 , the expected sample
size falls by four pairwise allocations, from 77 to 73;
the trial saves slightly more of the budget (£210,000)
and the model shows sling to be cost-effective for 91%
Table 1. Results for the 5000 resampled paths from the bootstrap and Monte Carlo analysis.
Average % change Standard deviation Minimum Maximum
Qmax = 250
Optimal Bayes Sequential
Sample size (pairwise allocations) – bootstrap 77 238 27 57 250
Sample size (pairwise allocations) – Monte Carlo 88 230 20 57 250
Change in budget (£000) – bootstrap 2196 213 110 2277 510
Change in budget (£000) – Monte Carlo 2151 210 82 2277 510
Posterior mean for cost-effectiveness
(£)– bootstrap
21853 – 1322 25900 3046
Posterior mean for cost-effectiveness
(£)– Monte Carlo
21820 – 449 24190 2617
Fixed sample size
Sample size (pairwise allocations) 250 – 0 250 250
Posterior mean for cost-effectiveness 21832 – 720 24047 1017
Qmax = 125
Optimal Bayes Sequential
Sample size (pairwise allocations) – bootstrap 73 242 19 57 125
Sample size (pairwise allocations) – Monte Carlo 84 233 16 57 125
Change in budget (£000) – bootstrap 2210 214 78 2277 0
Change in budget (£000) – Monte Carlo 2167 211 63 2277 0
Posterior mean for cost-effectiveness
(£)– bootstrap
21845 – 1347 25778 3670
Posterior mean for cost-effectiveness
(£)– Monte Carlo
21811 – 460 23900 2451
Fixed sample size
Sample size (pairwise allocations) 125 – 0 125 125
Posterior mean for cost-effectiveness 21804 – 988 24951 2100
Qmax = 250 Qmax = 125
Bootstrap Sling Surgery Total Sling Surgery Total
Optimal Bayes Sequential
First crossing lower part of stopping boundary 0.815 0.020 0.835 0.805 0.023 0.828
First crossing upper part of stopping boundary 0.102 0.063 0.165 0.106 0.066 0.172
Total 0.917 0.083 1 0.911 0.089 1
Fixed sample size
Total 0.993 0.007 1 0.961 0.039 1
Percentage changes in sample size reported in Column 3 are calculated as (a 125)=125 3 100, where a is the relevant average value from Column
2 and 125 refers to the number of pairwise allocations in the ProFHER trial. For rows which report a percentage change in the budget, the
percentage refers to the change in the number of pairwise allocations, (a 125), multiplied by the cost per pairwise allocation (£4080), expressed as
a percentage of the total budget of £1,470,000.
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of the bootstrapped paths, which is little change from
the 92% when Qmax = 250 .
Figure 4 presents some graphical summaries of the
bootstrap analysis. Figure 4(a) shows that, when
Qmax = 250 , approximately 37% of the resampled
paths stop the trial at the first interim look and approx-
imately 23% stop it at the second interim look, so that
approximately 60% of bootstrapped paths have a sam-
ple size that is approximately half of the one used in
the ProFHER trial (Figure 4(c)). Reducing Qmax to
125 pairwise allocations makes little difference (Figure
4(b) and (c)). Figure 4(d) shows that the relative fre-
quency histograms for the posterior mean for expected
incremental net monetary benefit at adoption are
almost identical and appear slightly right-skewed.
Sensitivity analysis
To investigate the sensitivity of our main results to dif-
ferent assumptions about how the data accumulated
over the course of the trial, we also carried out a Monte
Carlo simulation which took repeated draws of incre-
mental net monetary benefit from a normal distribution
with expected value equal to the value that was used for
the bootstrap (approximately 2£1808) and n0 = 2.
Results are also presented in Table 1 and labelled
‘Monte Carlo’. Averages are qualitatively in line with
those of the bootstrap analysis and standard deviations
are smaller. For example, when the maximum sample
size of the trial is set to 250 pairwise allocations, the
expected sample size of the trial is 30% lower (com-
pared with 38% lower in the bootstrap), the reduction
in the budget is 10% (compared with 13%) and the
posterior mean for expected incremental net monetary
benefit is almost unchanged.
A discussion of further sensitivity analysis is pre-
sented in the Supplemental Material.
Discussion and conclusion
With growing interest in the use of adaptive clinical
trials, there is a need to explore how new approaches
perform, from both economic and statistical perspec-
tives. Our application of a Bayesian decision-theoretic
model of a sequential clinical trial to the ProFHER
pragmatic trial suggests that it could have stopped the
trial early, saving about 5% of the research budget.
The bootstrap analysis suggests that the sample size
would have been reduced by approximately 38%, sav-
ing around 13% of the budget, with a probability of
0.92 of making a technology recommendation consis-
tent with that of the trial itself. It also shows a large
degree of variability in the trial’s sample size.
It is important to note that, although the model may
be applicable in a range of trial settings with a pragmatic
element, it will not be applicable to all trials. For exam-
ple, it is unlikely to be suitable for Type C trials, which
are more concerned with safety than with effectiveness or
cost-effectiveness, as well as trials where the length of
follow-up of the outcome of interest is close to the length
of the recruitment period (these present little or no scope
for using interim analyses) and trials where the health
outcome measure of interest is the time to an event rather
than a period of fixed duration (this breaks the model’s
assumption about a fixed period of follow-up).
We conclude with some directions for future research:
1. Approximately 37% of resampled paths from the
bootstrap analysis stop at the first interim analysis,
with a sample size equal to just under half of that
of the ProFHER trial. Given that about half of the
surgeons who responded to a recent survey23 stated
that they had changed practice because of
ProFHER, it is unlikely that such a sample size
will be deemed credible for changing practice. One
extension would be to investigate the sensitivity of
results to choice of follow-up period.
2. Some of the parameters used to populate the model
are difficult to estimate, suggesting that additional
sensitivity analysis is warranted. For example, the
size of the population to benefit is a function of
both the incidence rate and the time horizon over
which an adoption decision applies. Defining fixed
and variable costs may also be challenging, and the
Figure 3. Stopping boundaries for the two versions of the
model, together with the path for the posterior mean generated
using the trial’s data (black line, marker: ‘8’) and three resampled
paths from the bootstrap analysis (dashed lines, markers: ‘+ ’,
‘’ and ‘8’). X marks the first interim analysis at which the
posterior mean lies outside the stopping boundary (for both
versions of the model).
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CAT project14 may provide helpful guidance. The
costs of monitoring a sequential design may be
higher than those for a fixed design.
3. The model assumes that patients are randomised in
a pairwise manner to treatments, but there exists a
large statistical literature on the use of allocation-
adaptive randomisation in frequentist designs.24
4. The handling of missing data could be explored in
further sensitivity analysis. This matter is being
investigated as part of the ENACT project.15
5. The sampling variance is assumed to be known. This
requires that either it be estimated at the start of the
trial or that the methods of Chick et al.,13 Section 4,
are used for the case of unknown sampling variance.
6. We assume a prior mean that is equal to zero and
a prior variance which assigns a low weight to
prior information. Choice of the prior mean is
important because it determines whether no trial, a
fixed sample size trial or a sequential trial are the
preferred designs. It also affects the point at which
the Stage II path for the posterior mean starts.
Choice of the prior variance affects the weights
placed on the prior information and the data.
Although we believe that a non-informative prior
is reasonable for the ProFHER trial, it may not be
for other trials. This is another topic that is being
investigated further in the ENACT project.15
7. The stopping boundary could be compared with a
Bayesian design which uses a stopping rule based
on the probability that a technology is cost-effec-
tive, together with frequentist group sequential
stopping rules, as in Pertile et al.12
Figure 4. Graphical analysis of the bootstrap results: (a) relative frequency histogram for the number of pairwise allocations made
upon first crossing the stopping boundary (Qmax = 250), (b) relative frequency histogram for the number of pairwise allocations
made upon first crossing the stopping boundary (Qmax = 125), (c) empirical cumulative distribution functions for the number of
pairwise allocations made upon first crossing the stopping boundary and (d) relative frequency histograms for posterior mean for
E½ incremental net monetary benefit  once follow-up has concluded.
8 Clinical Trials 00(0)
Authors’ note
This is a proof of concept paper which is intended to illustrate
how the model presented may be populated retrospectively
with data from a randomised clinical trial. It is not intended
that the paper represents a comment on the health technolo-
gies themselves. The ProFHER trial was funded by the
National Institute for Health Research Health Technology
Assessment programme (project number ref 06/404/502). The
views expressed are those of the authors and not necessarily
those of the National Health Service, the National Institute
for Health Research or the Department of Health and Social
Care. An early version of this article was made available as
part of the working paper series of the Department of
Economics and Related Studies, University of York (DP 19/
01, http://ideas.repec.org/p/yor/yorken/19-01. html).
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